Fate Therapeutics FATE reported its Q4 earnings results on Monday, February 26, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Fate Therapeutics beat estimated earnings by 13.0%, reporting an EPS of $-0.45 versus an estimate of $-0.52.
Revenue was down $42.68 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.11 which was followed by a 9.0% drop in the share price the next day.
Here's a look at Fate Therapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.57 | -0.59 | -0.62 | -0.86 |
EPS Actual | -0.46 | -0.54 | -0.19 | -0.58 |
Revenue Estimate | 890K | 5.53M | 35.50M | 16.72M |
Revenue Actual | 1.94M | 933K | 58.98M | 44.36M |
To track all earnings releases for Fate Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.